In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rewind: BASF and DuPont Exit the Drug Business

Executive Summary

The modern drug industry was born out of the chemical industry-particularly the German chemical industry. And as the difference in the profit margins between the two industries grew in the 1960s and 70s, even those chemical players who still hadn't made much of a commitment to the drug business, like Dow Chemical and DuPont, jumped in. But the big bang which created the drug industry in the first place now looks to be on a kind of re-wind as those companies who never managed to build a big enough drug business get out of it. In part, the issue is comparative attractiveness. Hoechst's chemical business never really recovered from the shock of losing the CFC franchise to environmental concerns, but its pharmaceutical business grew. BASF and DuPont, on the other hand, weren't able to turn the corner in pharmaceuticals--and their chemical businesses never became so unattractive as to force their hands. That's why now they're getting out of the drug business and re-focusing their efforts on what they've done well.

You may also be interested in...

Viatris Will Tread A Different Path

By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.

EU Single Patent System On Course For 2020

Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.

Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA

A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts